RESUMEN
Mortality from asthma is apparently on the rise and, in some cases, may be due to the type and amount of medication used by the patient. As a result, the role of some commonly prescribed agents has changed in recent years. In this article, the authors review modifications in the use of currently available drugs, discuss new applications of drugs not traditionally used for asthma, and examine the rationale behind the development of entirely new classes of drugs.
Asunto(s)
Asma/tratamiento farmacológico , Corticoesteroides/uso terapéutico , Agonistas Adrenérgicos beta/uso terapéutico , Humanos , Antagonistas de Leucotrieno , Teofilina/uso terapéuticoRESUMEN
Castleman's disease is an uncommon lymphoproliferative disorder that manifests itself as a local or generalized tumor-like condition affecting both lymph nodes and nonnodal tissues, usually in the chest or abdomen. Only two prior examples involving the central nervous system had been reported when this patient was encountered. Very recently, three additional cases have been reported by Severson et al. We report the sixth case of Castleman's disease affecting the central nervous system, which occurred in a 63-year-old woman in whom the diagnosis was made after craniotomy for a mass lesion involving the dura over the frontal regions. Neuroradiological, clinical, and immunopathological characteristics of the case are presented. The lesion was treated with cranial irradiation and the patient is alive and symptom free three years after initial treatment.